EQT Revives Sale of Contact Lens Maker Ginko at $1bn-Plus Valuation

Why It Matters

The transaction signals renewed confidence in high‑growth healthcare consumer assets and could reset valuation benchmarks for ophthalmic devices. A successful exit would bolster EQT’s track record and provide liquidity in a market where private‑equity exits have softened.

Key Takeaways

• EQT re‑launches Ginko sale targeting $1 billion valuation
• Ginko's revenue grew 15% YoY, driven by premium lenses
• Sale aligns with EQT's focus on healthcare consumer brands
• Potential buyers include strategic OEMs and private‑equity rivals
• Deal could set benchmark for ophthalmic device valuations

Pulse Analysis

EQT’s decision to revive the sale of Ginko underscores a strategic pivot toward high‑margin, consumer‑focused healthcare assets. Ginko, known for its premium contact‑lens lines and a robust digital distribution network, has posted solid top‑line growth despite broader economic headwinds. By positioning the company at a $1 billion-plus valuation, EQT aims to capitalize on the sector’s resilience and the growing demand for vision‑correction products, especially as aging demographics and screen‑time habits drive lens adoption worldwide.

The broader private‑equity landscape has seen a dip in exit activity during Q1 2026, with deal counts falling across regions. Yet, niche healthcare segments remain attractive, offering stable cash flows and defensible market positions. EQT’s renewed push for Ginko reflects confidence that specialty medical devices can command premium multiples, even as banks tighten terms on private‑credit financing. Potential acquirers range from global OEMs seeking vertical integration to fellow PE firms looking to expand their health‑tech portfolios, creating a competitive bidding environment that could elevate final pricing.

For the contact‑lens market, Ginko’s sale could serve as a bellwether. The industry is experiencing a shift toward personalized, high‑performance lenses and subscription‑based models, trends that have boosted margins and customer loyalty. A successful transaction would likely encourage further consolidation, prompting rivals to explore similar exits or strategic partnerships. Investors and industry watchers should monitor how the deal unfolds, as it may set new valuation standards and influence capital allocation across the broader ophthalmic device sector.